| Поле DC | Значение | Язык |
|---|
| dc.contributor.author | Fedorov, V. N. | - |
| dc.contributor.author | Smirnov, N. A. | - |
| dc.contributor.author | Vdovichenko, V. P. | - |
| dc.contributor.author | Fedorova, T. B. | - |
| dc.contributor.author | Kerbenev, E. E. | - |
| dc.date.accessioned | 2022-05-04T13:41:07Z | - |
| dc.date.available | 2022-05-04T13:41:07Z | - |
| dc.date.issued | 2020 | - |
| dc.identifier.citation | Treatment of hepatitis induced by anti-tuberculosis drugs (experimental research) / V.N. Fedorov [et al.] // Research Results in Pharmacology. - 2020. - Vol.6, №3.-P. 33-39. - Doi: 10.3897/rrpharmacology.6.56453. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/46589 | - |
| dc.description.abstract | Tuberculosis is a widely spread infection. While treating patients for it, they are given simultaneously and for a long period 5-6 antibacterial drugs, which are, as a rule, bad for the liver. It quite often (up to 20%) causes drug-induced hepatitis. As experimental means of protecting the liver, the following peptides are suggested: chorionic gonadotropin, a recombinant drug of luteinizing hormone - luveris, and oligopeptide drugs: semax and selank | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | tuberculosis | ru |
| dc.subject | hepatoprotection | ru |
| dc.subject | hepatoprotector | ru |
| dc.subject | drug-induced liver lesions | ru |
| dc.subject | chorionic gonadotropin | ru |
| dc.subject | luteinizing hormone of hypophysis | ru |
| dc.subject | semax | ru |
| dc.subject | selank | ru |
| dc.title | Treatment of hepatitis induced by anti-tuberculosis drugs (experimental research) | ru |
| dc.type | Article | ru |
| Располагается в коллекциях: | Vol. 6, № 3
|
